These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 30460397)

  • 41. Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation.
    Orzan F; De Bacco F; Lazzarini E; Crisafulli G; Gasparini A; Dipasquale A; Barault L; Macagno M; Persico P; Pessina F; Bono B; Giordano L; Zeppa P; Melcarne A; Cassoni P; Garbossa D; Santoro A; Comoglio PM; Indraccolo S; Simonelli M; Boccaccio C
    Clin Cancer Res; 2023 Apr; 29(7):1252-1266. PubMed ID: 36648487
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma.
    Escudero L; Llort A; Arias A; Diaz-Navarro A; Martínez-Ricarte F; Rubio-Perez C; Mayor R; Caratù G; Martínez-Sáez E; Vázquez-Méndez É; Lesende-Rodríguez I; Hladun R; Gros L; Ramón Y Cajal S; Poca MA; Puente XS; Sahuquillo J; Gallego S; Seoane J
    Nat Commun; 2020 Oct; 11(1):5376. PubMed ID: 33110059
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer.
    Wang Y; Luo N; Gao Y; Wu Y; Qin X; Qi Y; Sun T; Tao R; Qi C; Liu B; Yuan S
    J Cancer Res Clin Oncol; 2023 May; 149(5):1679-1690. PubMed ID: 35583828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
    Ikeda S; Lim JS; Kurzrock R
    Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
    Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
    Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liquid biopsies for the diagnosis and surveillance of primary pediatric central nervous system tumors: a review for practicing neurosurgeons.
    Bounajem MT; Karsy M; Jensen RL
    Neurosurg Focus; 2020 Jan; 48(1):E8. PubMed ID: 31896088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
    Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
    Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
    Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
    Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases.
    Song Y; Liu P; Huang Y; Guan Y; Han X; Shi Y
    Curr Cancer Drug Targets; 2019; 19(8):666-673. PubMed ID: 30332963
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
    Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
    Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted mutation detection in breast cancer using MammaSeq™.
    Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
    Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating Tumor DNA Profiling Approach Based on In Silico Background Elimination Guides Chemotherapy in Nasopharyngeal Carcinoma.
    Li M; Xie S; Hou T; Shao T; Kuang J; Liu C; Qu Y; Lu C; Liu J; Liu X; Zhu L; Zhu L
    Clin Pharmacol Ther; 2024 May; 115(5):993-1006. PubMed ID: 38037868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas.
    Bobillo S; Crespo M; Escudero L; Mayor R; Raheja P; Carpio C; Rubio-Perez C; Tazón-Vega B; Palacio C; Carabia J; Jiménez I; Nieto JC; Montoro J; Martínez-Ricarte F; Castellvi J; Simó M; Puigdefàbregas L; Abrisqueta P; Bosch F; Seoane J
    Haematologica; 2021 Feb; 106(2):513-521. PubMed ID: 32079701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study.
    Li M; Hou X; Zheng L; Ma Y; Li D; Lv Y; Chen J; Zheng W; Shao Y; Mou Y; Chen L
    ESMO Open; 2022 Feb; 7(1):100305. PubMed ID: 34922300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concordance analysis between liquid biopsy (ctDNA) and tumor DNA molecular profiles from panel-based next-generation sequencing.
    Rodon Font N; No Garbarino Y; Díaz Castello O; Moya Amoros J; Barrios Sánchez P; Coroleu Lletget D; Lequerica Cabello MA; Borras Marcet J; Mecho Meca S; Escape I; Martinez-Agea J; Garcia E; Ferrer M; Puig Torrus X
    Rev Esp Patol; 2022; 55(3):156-162. PubMed ID: 35779881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.
    Chin YM; Takahashi Y; Chan HT; Otaki M; Fujishima M; Shibayama T; Miki Y; Ueno T; Nakamura Y; Low SK
    Cancer Sci; 2021 Jan; 112(1):454-464. PubMed ID: 33075187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.
    Baumgartner JM; Raymond VM; Lanman RB; Tran L; Kelly KJ; Lowy AM; Kurzrock R
    Ann Surg Oncol; 2018 Aug; 25(8):2400-2408. PubMed ID: 29948422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.
    Azad TD; Chaudhuri AA; Fang P; Qiao Y; Esfahani MS; Chabon JJ; Hamilton EG; Yang YD; Lovejoy A; Newman AM; Kurtz DM; Jin M; Schroers-Martin J; Stehr H; Liu CL; Hui AB; Patel V; Maru D; Lin SH; Alizadeh AA; Diehn M
    Gastroenterology; 2020 Feb; 158(3):494-505.e6. PubMed ID: 31711920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.